India revokes patent on Sutent, Pfizer to appeal Pharma Times Sutent (sunitinib) a treatment for liver and kidney cancer, was granted a patent in India in 2007 but that decision was challenged by generics specialist Cipla and Natco Pharma. India's Patent Board has backed the latter firm, saying that "the ... |
